Pharma Focus America

Totus Medicines and Lilly Forge Strategic Collaboration for Multi-Target Research

Friday, May 17, 2024

Totus Medicines has just announced a major collaboration with Eli Lilly and Company. They're teaming up to utilize Totus's innovative OmniDEL platform in discovering small molecule drug candidates for undisclosed targets identified by Lilly.

According to the agreement, Totus will employ its proprietary technology to create high-quality covalent compounds tailored to Lilly's specified targets. The collaboration provides Lilly and Totus with the option to exclusively pursue the development and commercialization of any promising compounds resulting from the research, with milestone payments tied to successful achievements.

Totus Medicines, expressed enthusiasm about the collaboration, highlighting Lilly's renowned status in the pharmaceutical field. He emphasized how this collaboration validates Totus's strategy in both partnering with established entities like Lilly and advancing its internal pipeline. Currently, Totus has a Phase 1 covalent PI3Kα inhibitor and an AKT covalent inhibitor in preclinical development, showcasing the company's dedication to driving innovations in drug discovery and development.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024